menu
    • menu
    [{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALKS 2680","moa":"OX2 receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DSP-0187","moa":"OX2 receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Sosei Group Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Centessa Pharmaceuticals \/ Sosei Group Corporation"},{"orgOrder":0,"company":"XWPharma","sponsor":"Panacea Venture","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"XW10172","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase I","graph3":"XWPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XWPharma \/ Panacea Venture","highestDevelopmentStatusID":"6","companyTruncated":"XWPharma \/ Panacea Venture"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"E2086","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Sleep","graph2":"Phase I","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fortrea","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Acetazolamide","moa":"||CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Fortrea","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fortrea \/ Incannex Healthcare","highestDevelopmentStatusID":"6","companyTruncated":"Fortrea \/ Incannex Healthcare"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORX750

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Sosei Group Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nxera Partner Centessa Reports Positive Ph 1 Data for ORX750 in Sleep-Deprived Volunteers

                            Details : ORX750 is an investigational, orally administered, highly potent and selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1.

                            Product Name : ORX750

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 09, 2024

                            Lead Product(s) : ORX750

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Sosei Group Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alkermes Plc

                            Ireland arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Alkermes Plc

                            Ireland arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALKS 2680

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alkermes Announces Positive Phase 1b Results for ALKS 2680 in Narcolepsy Type 2 Patients

                            Details : ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist, which is being evaluated for the treatment of narcolepsy type 2 & idiopathic hypersomnia.

                            Product Name : ALKS 2680

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 04, 2024

                            Lead Product(s) : ALKS 2680

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eisai

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Eisai

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : E2086

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EISAI TO BEGIN ENROLLING STUDY IN PATIENTS WITH NARCOLEPSY

                            Details : E2086 an oral novel selective orexin-2 agonist, being investigated for narcolepsy type I in adults. Nonclinical studies have demonstrated statistically significant reductions in rates of cataplexy.

                            Product Name : E2086

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 07, 2024

                            Lead Product(s) : E2086

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sosei Group Corporation

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Sosei Group Corporation

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORX750

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Centessa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals

                            Details : ORX750 is an investigational, orally administered, highly potent and selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1.

                            Product Name : ORX750

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 30, 2024

                            Lead Product(s) : ORX750

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Centessa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Fortrea

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Fortrea

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetazolamide,Tetrahydrocannabinol

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Incannex Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Incannex Engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Trea...

                            Details : Fortrea will manage Incannex's IND opening Phase 2/3 clinical trial investigating IHL-42X which is a synergistic composition of dronabinol, a synthetic form of Tetrahydrocannabinol, and acetazolamide, a carbonic anhydrase inhibitor, for treatment of obst...

                            Product Name : IHL-42X

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 18, 2023

                            Lead Product(s) : Acetazolamide,Tetrahydrocannabinol

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Incannex Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MindBio Therapeutics

                            Australia arrow
                            Indo Livestock Expo
                            Not Confirmed

                            MindBio Therapeutics

                            Australia arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LSD

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MindBio Therapeutics Breakthrough Discovery in Microdosing Clinical Trial Reveals Significant Positive Effects...

                            Details : Lysergic Acid Diethylamide is a potent psychoactive substance which binds to the 5-HT2A receptor as a partial agonist and 5-HT1A as an agonist. It is being investigated as Improves Sleep.

                            Product Name : MB22001

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            June 14, 2023

                            Lead Product(s) : LSD

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Incannex Healthcare

                            Australia arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Incannex Healthcare

                            Australia arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetazolamide,Tetrahydrocannabinol

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Positive Pre-IND Meeting with US FDA for IHL-42X for Obstructive Sleep Apnoea

                            Details : IHL-42X (dronabinol) is a fixed-dose combination of dronabinol and acetazolamide that is being developed as a treatment for obstructive sleep apnoea (‘OSA’) in adults.

                            Product Name : IHL-42X

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 17, 2022

                            Lead Product(s) : Acetazolamide,Tetrahydrocannabinol

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            KemPharm

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            KemPharm

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexmethylphenidate

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathi...

                            Details : The data suggest that KP1077 (serdexmethylphenidate) produces a smoother, more gradual release of d-MPH that may avoid the adverse events associated with large and rapid exposure fluctuations that may be experienced with other stimulant-based therapies.

                            Product Name : KP1077

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            May 05, 2022

                            Lead Product(s) : Dexmethylphenidate

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            KemPharm

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            KemPharm

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexmethylphenidate

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenida...

                            Details : Prodrug of d-methylphenidate, is sole API in KP1077, a potential first-ever therapeutic treatment for Idiopathic Hypersomnia, a neurological disorder marked by significant, detrimental effects on nighttime sleep as well as daytime sleepiness/wakefulness.

                            Product Name : KP1077

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            April 19, 2022

                            Lead Product(s) : Dexmethylphenidate

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sumitomo

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Sumitomo

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DSP-0187

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Jazz Pharmaceuticals

                            Deal Size : $1,140.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP...

                            Details : Under the agreement, Jazz will receive an exclusive license to develop and commercialize narcolepsy and sleep drug DSP-0187/JZP441 in U.S., Europe and other territories except Japan, China and other Asia/Pacific countries and regions, where Sumitomo Phar...

                            Product Name : JZP441

                            Product Type : Other Small Molecule

                            Upfront Cash : $50.0 million

                            April 05, 2022

                            Lead Product(s) : DSP-0187

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Jazz Pharmaceuticals

                            Deal Size : $1,140.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth